All News

Quote of the day “Don’t be too quick to call it negative” by Marco Gattorno on looking for systemic Autoinflammatory disease (SAID) when there is the clinical suspicion #EULAR2022 @RheumNow https://t.co/SjARIlDjtR

Agree. Love to understand: - standardisation for whole body MRI - how it does not compromise image quality vs limited field - clear explanation of benefit vs limited field, where it exists Its inappropriate use in the worried well by charlatans has skewed me #EULAR2022 @RheumNow https://t.co/3LRz0OOAEF

ARD & RMD Open on Twitter: "What are the indications for whole body MR…

Castrejon et al. BIOBADASER registry study. Cancer risk with various bDMARDs. Overall I don't think there is a difference here. Lowest in IL17i and highest in abatacept but older and comorbidity confounders @RheumNow #EULAR2022 #POS1439 https://t.co/gfv78ouOTJ

Kristensen et al. IL23i Risankizumab improves fatigue, health related quality of life, work productivity in PsA. @RheumNow #EULAR2022 POS1042 https://t.co/fnoCZCpwNM

Please see my short video on Promising Safety Outlook for Rituximab and Baricitinib in Vaccinated Patients #EULAR2022 @RheumNow https://t.co/bqzdWIzoOg

Promising Safety Outlook for Rituximab and Baricitinib in Vaccinated Patients -…

De Miguel et al. Subclinical GCA in PMR shows different US pattern to classic GCA. Less cranial involvement and more isolated extra-cranial. About what you would have expected given clinical manifestations. @RheumNow #EULAR2022 POS0248 https://t.co/i9IZBdF1vQ

Joanna Robson @Robsonjo4 et al. Disease specific outcome measure for GCA (badly needed!) GCA-PROM. Demonstrated internal and external validity in measuring health related quality of life in GCA patients. @RheumNow #EULAR2022 POS0003 https://t.co/F8pLvlzqD1

Please see my video interview with Dr @LucyCarter6 on her prize winning #EULAR2022 abstract #OP0234 on transcriptomic analyses of peripheral bloods in identifying modules that predict OR protect progression from ANA+ to #lupus or CTD @RheumNow https://t.co/c3khwFzx79

Dr. Lucy Carter on RNA-Seq analysis to determine who's at risk for SLE - Yo…

Nash @drpnash et al. IL23i guselkumab improves pain in PsA. Good to see as it is a really important PRO, but there is still significant work to do, week 24 - 60% had <50% and 37% had <20% improvement in pain @RheumNow #EULAR2022 POS1044 https://t.co/H92r4leslT

Tillett et al. Baseline characteristics and achievement of MDA at week 24 with IL23i guselkumab in bDMARD experienced patients. Pattern of joint (wrist vs shoulder/hand) and skin (scalp vs hand/foot) involvement, as well as male sex, predictive @RheumNow #EULAR2022 POS1051 https://t.co/lHOTgMWgMA

den Broeder et al. Follow-up to REDO study. Ultra-low dose RTX non-inferior for DAS28CRP. 1000mg 2.2 (2.0-2.4), 500mg 2.2 (2.1-2.4), 200mg 2.3 (2.2-2.5) (all given 6-monthly). Small effect by received dose though (0.15 per 1000mg) @RheumNow #EULAR2022 POS0652 https://t.co/hfSw9ndQpk

Sousa et al. Anti-Ku disease. Cluster analysis (Ku alone, Ku with other abs) asking is is a distinct entity. In isolated anti-Ku+ maybe so, characterised by Raynauds (41%), arthritis (26%), sicca (26%), myositis (15%), ILD (15%) @RheumNow #EULAR2022 POS0861 https://t.co/IboWzMYFMB

Video: What Patients Want and Are Willing to Risk with SLE Dr. Kathryn Dao discusses abstract POS0086 at #EULAR2022 which looks at real life lupus patient preferences who are willing to undergo risk in order to get the treatment outcome that they desire. https://t.co/kHZz5MrZi2 https://t.co/XRsoXHR1ce

https://bit.ly/3NiaNlu

Campaniello et al. Ultra-low dose RTX (500/1000mg once a year) vs low dose RTX (500/1000mg 6-monthly) for maintenance in AAV. Comparable relapse free survival 22.7% vs 21.2%, lower severe infection 10.5% vs 26.8% @RheumNow #EULAR2022 POS0837 https://t.co/uBgEmhLUzv

Prof McInnes @IainBMcInnes1 et al. IL23i guselkumab efficacy maintained irrespective of baseline characteristics of patients. I kind of wish in some of these studies that we would see big differences to help us select between agents! @RheumNow #EULAR2022 POS0072 https://t.co/zJWvpwcDkt

WIN-Lupus is no winner. Stopping #MMF or #Azathioprine after 2 to 3 yrs of well controlled #SLE is a loser due to more #lupus nephritis. Diff from RCT of MMF taper in remission pts. @RheumNow @eular_org #EULAR2022 https://t.co/Ut8uRonrNP

Richard Conway on Twitter: "WIN-Lupus. RCT of stopping treatment in SLE. A…

Dr Terrier @TerrierBen Mepolizumab gives clinical benefit in EGPA in terms of remission at week 36/48 and accrued remission. Benefit irrespective of presence of vasculitic features, ANCA status, clinical features, etc @RheumNow #EULAR2022 POS0836 https://t.co/GHwt1WNZEs

Adami et al Real world fracture prevention with osteoporosis meds. 30% lower risk with bisphosphonate, 60% denosumab, 90% teriparatide. Bisphosphonates only showed effect after 1 year. Not sure I buy it, very different to RCTs. @RheumNow #EULAR2022 OP0239 https://t.co/6qaYAVw73Q https://t.co/bNwWmxxSeF

EULAR Abstract Archive

Mulder et al. COMPLETE-PsA trial. MTX+LEF vs MTX mono. 78 patient RCT. LEF 20mg, MTX 25mg. MTX+LEF more effective (MDA 59% vs 32%) but less well tolerated (3 SAE vs 0; N+V, diarrhoea. No mention of LFTs). @RheumNow #EULAR2022 POS0078 https://t.co/2D84EFmabc

So what diet to follow with autoimmunity in mind? So many, all with different instructions. Let’s concentrate on where they agree: yes to fruits & vegetables no to emulsifiers & processed foods #EULAR2022 @RheumNow https://t.co/I9abweQOyZ

Topics

All News

Do you get our email newsletter?